

Investor webinar

Sydney, Australia – 31 October 2023 – Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that CEO and Managing Director Riccardo Canevari will conduct an investor webinar to discuss the \$10 million entitlement offer announced this morning and provide an update on the most recent developments for the Company. An opportunity to ask questions will also be provided.

When: 10:30am AEDT, Tuesday 31 October 2023

Register at: https://us02web.zoom.us/webinar/register/WN_2r2J-pcoTgm7txlgx3XfRQ

Upon registering attendees will receive an email containing information about joining the webinar.

A recording will be available at the above link soon after the conclusion of the live session, with the replay to also be made available via Radiopharm's website and social media channels.

Questions can be sent in advance of the webinar to matt@nwrcommunications.com.au.

Authorised on behalf of the Radiopharm Theranostics board of directors by Executive Chairman Paul Hopper.

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com

Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>